Profile data is unavailable for this security.
About the company
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
- Revenue in USD (TTM)50.83m
- Net income in USD-171.53m
- Incorporated2022
- Employees113.00
- LocationScilex Holding Co960 San Antonio RoadPALO ALTO 94303United StatesUSA
- Phone+1 (650) 516-4310
- Fax+1 (302) 636-5454
- Websitehttps://www.scilexholding.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc | 0.00 | -49.67m | 64.10m | 20.00 | -- | 41.37 | -- | -- | -1.67 | -1.67 | 0.00 | 0.4079 | 0.00 | -- | -- | 0.00 | -168.84 | -83.69 | -450.38 | -99.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Hongchang International Co Ltd | 5.42m | -208.79k | 66.15m | 8.00 | -- | 1.63 | -- | 12.21 | -0.0004 | -0.0004 | 0.0104 | 0.0784 | 0.0991 | 5.50 | 37.20 | -- | -0.2731 | -7.98 | -0.2965 | -10.94 | 4.51 | 11.47 | -2.76 | -64.88 | 4.64 | -- | 0.3169 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 67.19m | 217.00 | -- | 0.4959 | -- | 21.13 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 22.06m | -30.97m | 70.36m | 176.00 | -- | 5.08 | -- | 3.19 | -2.23 | -2.23 | 1.59 | 1.03 | 0.32 | 0.9265 | 2.03 | 125,312.50 | -43.04 | -34.75 | -66.19 | -46.91 | 54.31 | 55.98 | -134.50 | -153.72 | 2.32 | -- | 0.58 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 98.92m | -1.24m | 71.10m | 237.00 | -- | 2.44 | 49.86 | 0.7188 | -0.0496 | -0.0496 | 3.23 | 0.9015 | 1.80 | 14.45 | 10.84 | 417,371.30 | -2.25 | -46.29 | -3.34 | -65.38 | 16.91 | 4.66 | -1.25 | -36.51 | 2.00 | 0.3194 | 0.2654 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Journey Medical Corp | 57.77m | -18.34m | 77.43m | 58.00 | -- | 9.87 | -- | 1.34 | -0.9276 | -0.9276 | 2.93 | 0.5271 | 0.889 | 2.16 | 6.19 | 996,051.80 | -28.22 | -- | -76.21 | -- | 57.32 | -- | -31.74 | -- | 1.03 | -13.65 | 0.6582 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 77.57m | 220.00 | -- | 0.33 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.37m | 35.00 | 391.37 | 348.44 | -- | 35.44 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Assertio Holdings Inc | 125.76m | -68.49m | 92.07m | 53.00 | -- | 0.7056 | -- | 0.7321 | -0.7212 | -0.7212 | 1.32 | 1.37 | 0.3834 | 0.9052 | 2.34 | 2,372,887.00 | -20.88 | -21.51 | -30.33 | -32.05 | 70.31 | 88.68 | -54.46 | -62.10 | 1.57 | -- | 0.2293 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Scilex Holding Co | 50.83m | -171.53m | 105.77m | 113.00 | -- | -- | -- | 2.08 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 125.23m | 5.50k | 2.13 | 3.18 | 1.80 | 0.3024 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -22.96m | 132.36m | 1.00 | -- | 299.40 | -- | -- | -0.8145 | -0.8145 | 0.00 | 0.0149 | 0.00 | -- | -- | 0.00 | -721.99 | -- | -1,752.70 | -- | -- | -- | -- | -- | -- | -2.06 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Puma Biotechnology Inc | 243.57m | 23.24m | 142.35m | 185.00 | 6.11 | 2.00 | 4.09 | 0.5845 | 0.475 | 0.475 | 5.03 | 1.45 | 1.15 | 17.91 | 5.83 | 1,316,589.00 | 10.95 | -12.21 | 18.85 | -20.53 | 69.29 | 78.78 | 9.54 | -11.79 | 1.40 | 3.61 | 0.5234 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Data as of Nov 21 2024. Currency figures normalised to Scilex Holding Co's reporting currency: US Dollar USD
14.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 7.48m | 3.90% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 6.00m | 3.13% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.61m | 2.92% |
| Armistice Capital LLCas of 30 Sep 2024 | 3.51m | 1.83% |
| Millennium Management LLCas of 30 Sep 2024 | 1.46m | 0.76% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.30m | 0.68% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 770.72k | 0.40% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 627.04k | 0.33% |
| Rafferty Asset Management LLCas of 30 Sep 2024 | 620.13k | 0.32% |
| BlackRock Advisors LLCas of 30 Sep 2024 | 580.20k | 0.30% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
